Astrana Health (NASDAQ:ASTH) Given New $50.00 Price Target at BTIG Research

Astrana Health (NASDAQ:ASTH) had its target price boosted by stock analysts at BTIG Research from $40.00 to $50.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price objective indicates a potential upside of 38.58% from the company’s current price.

ASTH has been the subject of several other reports. Weiss Ratings upgraded Astrana Health from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Zacks Research upgraded Astrana Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, March 11th. Truist Financial raised their price objective on Astrana Health from $37.00 to $38.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Finally, Robert W. Baird raised their price objective on Astrana Health from $37.00 to $40.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 15th. Six analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $38.14.

Astrana Health Trading Up 2.4%

Shares of NASDAQ:ASTH opened at $36.08 on Friday. Astrana Health has a 52-week low of $18.08 and a 52-week high of $36.20. The stock has a market cap of $2.01 billion, a price-to-earnings ratio of 78.44 and a beta of 0.98. The company has a quick ratio of 1.40, a current ratio of 1.40 and a debt-to-equity ratio of 1.25. The business has a 50-day moving average price of $27.38 and a 200-day moving average price of $25.67.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.45. Astrana Health had a return on equity of 5.59% and a net margin of 0.71%.The firm had revenue of $965.10 million during the quarter, compared to analysts’ expectations of $949.21 million. During the same period last year, the business posted $0.42 earnings per share. The company’s revenue for the quarter was up 55.6% compared to the same quarter last year. Equities analysts predict that Astrana Health will post 1.44 EPS for the current year.

Institutional Trading of Astrana Health

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. 325 Capital LLC grew its holdings in Astrana Health by 54.0% during the fourth quarter. 325 Capital LLC now owns 1,839,076 shares of the company’s stock worth $45,627,000 after acquiring an additional 645,123 shares during the period. State Street Corp grew its holdings in Astrana Health by 6.2% during the fourth quarter. State Street Corp now owns 1,675,516 shares of the company’s stock worth $41,570,000 after acquiring an additional 98,064 shares during the period. Dimensional Fund Advisors LP grew its holdings in Astrana Health by 12.5% during the first quarter. Dimensional Fund Advisors LP now owns 1,368,079 shares of the company’s stock worth $33,545,000 after acquiring an additional 152,267 shares during the period. Geode Capital Management LLC grew its holdings in Astrana Health by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 1,028,168 shares of the company’s stock worth $25,513,000 after acquiring an additional 12,212 shares during the period. Finally, Wellington Management Group LLP grew its holdings in Astrana Health by 418.3% during the fourth quarter. Wellington Management Group LLP now owns 738,853 shares of the company’s stock worth $18,331,000 after acquiring an additional 596,293 shares during the period. 52.77% of the stock is owned by institutional investors and hedge funds.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.